Expression, methylation and prognostic feature of EMILIN2 in Low-Grade-Glioma

• DOI: 10.1016/j.brainresbull.2021.07.013
• Publication Date: 2021-07-16T16:19:40Z
• Authors: Li-chong Wang; Wen-yao Cui; Zhe Zhang; Zi-long Tan; Qiao-li Lv; Shu-hui Chen; Xiao-li Shen
• Keywords: Adult; Male; 0301 basic medicine; Aging; Brain Neoplasms; Gene Expression Profiling; Glioma; Kaplan-Meier Estimate; Middle Aged; Prognosis; Methylation; Polymerase Chain Reaction; Survival Analysis; 3. Good health; Gene Expression Regulation, Neoplastic; 03 medical and health sciences; Predictive Value of Tests; Biomarkers, Tumor; Humans; Female; Transcriptome; Glycoproteins

Low-grade gliomas (LGGs) are slow-growing brain cancer in central nervous system neoplasms. EMILIN2 is an extracellular matrix (ECM) protein which could influence the progress of some tumour which is unclear in LGG. In our study, the methylation, expression, prognosis and immune value of EMILIN2 in LGG were analysed through bioinformatics analysis. We analysed the LGG data from The Cancer Genome Atlas (TCGA) and discovered that the EMILIN2 expression, negatively correlated to the EMILIN2 methylation, could predict a poor prognosis and was associated with different clinical parameters. Moreover, univariate and multivariate Cox regression were performed in CGGA, which showed that the EMILIN2 could be an independent prognostic biomarker in LGG. Moreover, EMILIN2 expression showed a correlation with gene makers in some immune cells, which identified the significance of EMILIN2 in immune infiltration. Finally, we used RT-PCR to verify the EMILIN2 expression level in different grades which showed there were significantly different (P < 0.05). Similarly, high expression of EMILIN2 could predict a poor prognosis (P = 0.0078). In conclusion, EMILIN2 could act as an independent prognostic biomarker which might be associated with the malignancy and development of gliomas and play a crucial role in glioma in immune infiltration.